dstock07734
8 hours ago
Just some publications from Dr. Lisa Butterfield, a world-renowned scientist on DC vaccine. The following are just for illustration purpose. There are more papers that she coauthored with Andres Salazar or acknowledged him.
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma
Sabine Mueller,1,2,3,4 Jared M. Taitt,2 Javier E. Villanueva-Meyer,5 Erin R. Bonner,6 Takahide Nejo,2 Rishi R. Lulla,7 Stewart Goldman,8 Anu Banerjee,2,3 Susan N. Chi,9 Nicholas S. Whipple,10 John R. Crawford,11 Karen Gauvain,12 Kellie J. Nazemi,13 Payal B. Watchmaker,2 Neil D. Almeida,14 Kaori Okada,2 Andres M. Salazar,15 Ryan D. Gilbert,2 Javad Nazarian,4,6 Annette M. Molinaro,2 Lisa H. Butterfield,16,17 Michael D. Prados,2,3 and Hideho Okada2,16,18
https://www.jci.org/articles/view/140378
559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients
Kristin Shotts1, Timothy Howes1, Jia Yu1, Julie Densmore1, Diane Da Silva1, Dinesh Kumar1, Sandra Santulli-Marotto1, Christopher Cabanski1, Elaine Eisenbeisz1, Geoffrey Ivison2, Aaron Mayer2, Jonni Moore3, Derek Jones3, Kimberly Kraynyak4, Alex Dolgoter4, Richard Chen5, Lisa Butterfield1, Theresa LaVallee1, Samantha Bucktrout1, Lacey Padron1, Ute Dugan1, Michael Yellin6, Tibor Keler6, Jill O'Donnell-Tormey7, Justin Fairchild1, Lisa Salvador8, Kristopher Wentzel9, Lawrence Fong10, Sumit Subudhi11, Nina Bhardwaj12, Karen Autio13 and Matthew Galsky12
Acknowledgements We extend our gratitude to the patients, their families, the clinical investigators, and their site staff members who are making this trial possible. We would also like to thank Carri Browne, Christopher Perry, and Lancelote Leong at Parker Institute for Cancer Immunotherapy (PICI) for operations leadership of the trial. We thank Maria Jaimes and Quentin Low from Cytek Biosciences for spectral flow method development and sample analysis. We thank Jay Campbell (CRI), Samik Upadhaya (CRI), Andres Salazar (Oncovir) and Silvia Boffo (BMS) for their contributions. We thank Bristol Myers Squibb (BMS), Celldex, Oncovir and Inovio for collaboration and study drugs. The study was funded by Cancer Research Institute, BMS and PICI.
https://jitc.bmj.com/content/10/Suppl_2/A585
Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With a-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Authors: Hideho Okada okadah@upmc.edu, Pawel Kalinski, Ryo Ueda, Aki Hoji, Gary Kohanbash, Teresa E. Donegan, Arlan H. Mintz, Johnathan A. Engh, David L. Bartlett, Charles K. Brown, Herbert Zeh, Matthew P. Holtzman, Todd A. Reinhart, Theresa L. Whiteside, Lisa H. Butterfield, Ronald L. Hamilton, Douglas M. Potter, Ian F. Pollack, Andres M. Salazar, and Frank S. Lieberman
https://ascopubs.org/doi/full/10.1200/JCO.2010.30.7744
Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Hideho Okada; Lisa H. Butterfield; Ronald L. Hamilton; Aki Hoji; Masashi Sakaki; Brian J. Ahn; Gary Kohanbash; Jan Drappatz; Johnathan Engh; Nduka Amankulor; Mark O. Lively; Michael D. Chan; Andres M. Salazar; Edward G. Shaw; Douglas M. Potter; Frank S. Lieberman
https://aacrjournals.org/clincancerres/article/21/2/286/245329/Induction-of-Robust-Type-I-CD8-T-cell-Responses-in
Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study
Ian F. Pollack, Regina I. Jakacki, Lisa H. Butterfield, Ronald L. Hamilton, Ashok Panigrahy, Daniel P. Normolle, Angela K. Connelly, Sharon Dibridge, Gary Mason, Theresa L. Whiteside & Hideho Okada
Acknowledgments
UPCI Clinical Research Services for regulatory management, Andres Salazar, Oncovir, Inc., for provision of poly-ICLC, physicians who referred their patients, and the patients and families who participated in this trial.
https://link.springer.com/article/10.1007/s11060-016-2245-3
dstock07734
9 hours ago
In case, the longs still have doubt. Note that for the first five years the research project used Nivolumab which was replaced with Pembrolizumab starting in 2022. Merck pushed BMS out of the poject?
2024
https://reporter.nih.gov/search/xkk-VGQ1UUOqhb8O81ygjA/project-details/10906762
2023
https://reporter.nih.gov/search/nIYnpxNtzUu9Ey0NkNdBqA/project-details/10673749
2022
https://reporter.nih.gov/search/nIYnpxNtzUu9Ey0NkNdBqA/project-details/10496439
2021
https://reporter.nih.gov/search/8BIQlZadTUm8eOduhRzk9A/project-details/10225550
2020
https://reporter.nih.gov/search/8BIQlZadTUm8eOduhRzk9A/project-details/9983047
2019
https://reporter.nih.gov/search/uNeRxUSW0UeV4frdTW_JQg/project-details/9752974
2018
https://reporter.nih.gov/search/uNeRxUSW0UeV4frdTW_JQg/project-details/9543452
2017
https://reporter.nih.gov/search/uNeRxUSW0UeV4frdTW_JQg/project-details/9357417
PROJECT SUMMARY/ABSTRACT – Project 1 The lack of effective treatments for glioblastoma (GBM) patients remains a significant health problem and highlights the need for novel and innovative approaches. Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells in the brain. For the past 15 years, our group and others have been testing active vaccination strategies, such as dendritic cells (DC) pulsed with tumor lysate, to induce antitumor immunity in glioblastoma patients. From the interim results of the clinical trial we initiated in our current SPORE funding period, we found that in addition to inducing T-cell infiltration into brain tumors, DC vaccination + anti-PD1 blockade may also create a pro-inflammatory environment within the tumor that induces the immigration of immunosuppressive myeloid cells (TIM). These cells are phenotypically similar to the myeloid cells that dominantly attenuate the T-cell response to chronic viral infections, and may counteract the effective anti-tumor T-cell responses induced by DC vaccination within the tumor microenvironment. Therapies that target myeloid cells within the tumor microenvironment represent a promising new strategy. As such, inhibition of these myeloid cells using a CSF-1R inhibitor, in conjunction with autologous tumor lysate-pulsed DC vaccination (ATL-DC) and PD-1 mAb blockade, resulted in significantly prolonged survival in tumor-bearing animals with large, well-established intracranial (i.c.) gliomas. Our hypothesis is that myeloid cells mediate adaptive immune resistance in response to T cell activation induced by immunotherapy. In this SPORE Project renewal, we have planned a series of novel pre-clinical studies to re- polarize myeloid cells, to optimize how the timing and sequence of immunotherapy can influence ant-tumor immunity, and a new clinical trial to test the first-in-human combination of a new brain penetrant CSF-1R inhibitor (CSF-1Ri; PLX3397, Daiichi-Sankyo) with DC vaccination and PD-1 mAb blockade (Pembrolizumab, Merck) in patients with newly diagnosed GBM. A better understanding of the biology of these cellular interactions will provide insight into more effective ways to induce therapeutic anti-tumor immune responses for this deadly type of brain tumor. These studies span the continuum of translational research in brain tumor immunotherapy, and will likely provided informative new insights for the development of new, rational immune-based strategies for brain tumor patients.
819 Temporal influence of PD-1 blockade after vaccination on macrophage-driven CD8+ T cell exhaustion within the glioblastoma microenvironment
https://jitc.bmj.com/content/12/Suppl_2/A927
Conclusions This study reveals that timing may impact how ATL-DC and aPD1 combined therapies can alter the immune landscape of GBM and highlights tumor-associated macrophages as a major obstacle to clinical benefit. Future strategies targeting these populations or blocking their immunosuppressive interactions with anti-tumor CD8+ T cells hold promise for improving the efficacy of immunotherapies in GBM.